Novo Nordisk A/S $NVO Holdings Lifted by Dynamic Advisor Solutions LLC

Dynamic Advisor Solutions LLC increased its position in shares of Novo Nordisk A/S (NYSE:NVO) by 70.0% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 52,856 shares of the company’s stock after acquiring an additional 21,767 shares during the period. Dynamic Advisor Solutions LLC’s holdings in Novo Nordisk A/S were worth $2,689,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the business. Beacon Financial Group lifted its holdings in Novo Nordisk A/S by 4.3% in the 3rd quarter. Beacon Financial Group now owns 4,307 shares of the company’s stock valued at $239,000 after acquiring an additional 178 shares during the last quarter. Kavar Capital Partners Group LLC grew its stake in shares of Novo Nordisk A/S by 0.6% in the 3rd quarter. Kavar Capital Partners Group LLC now owns 32,631 shares of the company’s stock worth $1,811,000 after purchasing an additional 200 shares during the last quarter. SeaBridge Investment Advisors LLC grew its stake in shares of Novo Nordisk A/S by 5.7% in the 3rd quarter. SeaBridge Investment Advisors LLC now owns 3,735 shares of the company’s stock worth $207,000 after purchasing an additional 200 shares during the last quarter. Joel Isaacson & Co. LLC raised its holdings in shares of Novo Nordisk A/S by 1.0% in the 3rd quarter. Joel Isaacson & Co. LLC now owns 21,084 shares of the company’s stock worth $1,170,000 after purchasing an additional 200 shares in the last quarter. Finally, Revolve Wealth Partners LLC raised its holdings in shares of Novo Nordisk A/S by 8.7% in the 4th quarter. Revolve Wealth Partners LLC now owns 2,490 shares of the company’s stock worth $214,000 after purchasing an additional 200 shares in the last quarter. 11.54% of the stock is currently owned by institutional investors.

Key Stories Impacting Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: FDA clears a higher-dose formulation of Wegovy, which can deepen Novo Nordisk’s obesity franchise and support sales/price power for its semaglutide lineup. FDA Clears NVO’s Higher Dose of Wegovy
• Positive Sentiment: Novo Nordisk launched a Phase 1 study of LX9851, an oral non‑incretin obesity candidate licensed from Lexicon, expanding the pipeline beyond injectable semaglutides and offering long‑term upside if oral assets succeed. Lexicon and Novo Nordisk Announce Phase 1
• Positive Sentiment: Ongoing share repurchase programme (part of up to DKK 15bn plan) supports EPS and signals management confidence, which can be a near‑term technical tailwind. Novo Nordisk A/S – share repurchase programme
• Neutral Sentiment: Analyst and valuation pieces are mixed: some highlight Novo’s entrenched market position and recent approvals, while others warn of slowing growth and competition—contributing to divergent investor views on valuation. Novo Nordisk Valuation Check As LX9851 Expands
• Negative Sentiment: Indian patent expiry has opened the floodgates: multiple Indian manufacturers launched low‑cost generics of Ozempic/Wegovy (semaglutide), cutting prices by ~70% locally and setting a precedent for aggressive generic competition in price‑sensitive markets. This raises long‑term pricing and volume risk outside core markets. Indian drugmakers flood market with cheaper versions
• Negative Sentiment: Multiple reports emphasize cheap generic launches in India and other local markets (coverage by CNBC, DrugStoreNews, Moby), underscoring immediate revenue pressure where patent protection has lapsed and the risk of parallel imports or international pricing pressure over time. India launching cheap weight-loss drugs

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on the stock. JPMorgan Chase & Co. restated a “neutral” rating on shares of Novo Nordisk A/S in a report on Tuesday, February 24th. TD Cowen cut Novo Nordisk A/S from a “buy” rating to a “hold” rating and set a $42.00 price target on the stock. in a report on Tuesday, March 10th. Nordea Equity Research downgraded Novo Nordisk A/S to a “hold” rating in a research report on Tuesday, February 24th. Citigroup initiated coverage on Novo Nordisk A/S in a research note on Tuesday, January 27th. They set a “neutral” rating for the company. Finally, CICC Research started coverage on Novo Nordisk A/S in a report on Friday, January 9th. They issued an “outperform” rating and a $73.50 target price on the stock. Four analysts have rated the stock with a Buy rating, eighteen have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Novo Nordisk A/S has an average rating of “Hold” and a consensus price target of $65.56.

Novo Nordisk A/S Trading Up 0.8%

Shares of NYSE NVO opened at $36.81 on Tuesday. Novo Nordisk A/S has a one year low of $35.85 and a one year high of $81.44. The firm has a market capitalization of $164.36 billion, a PE ratio of 10.61 and a beta of 0.74. The company has a current ratio of 0.80, a quick ratio of 0.57 and a debt-to-equity ratio of 0.61. The business has a 50-day moving average price of $47.76 and a two-hundred day moving average price of $50.93.

Novo Nordisk A/S (NYSE:NVO) last issued its earnings results on Tuesday, February 3rd. The company reported $1.01 earnings per share for the quarter, beating analysts’ consensus estimates of $0.90 by $0.11. The company had revenue of $12.43 billion for the quarter, compared to the consensus estimate of $11.97 billion. Novo Nordisk A/S had a return on equity of 68.91% and a net margin of 33.03%. As a group, analysts predict that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Novo Nordisk A/S Announces Dividend

The business also recently disclosed a dividend, which will be paid on Wednesday, April 8th. Shareholders of record on Monday, March 30th will be paid a $1.2751 dividend. This represents a yield of 541.0%. The ex-dividend date is Monday, March 30th. Novo Nordisk A/S’s dividend payout ratio is currently 23.63%.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.